News
-
Novartis Steps in to Help Seed a Michigan Spinout’s Move into the Clinic with New Eye Drug
-
ONL Therapeutics Strengthens Leadership with Addition to Board of Directors and Expansion of Operations Team
-
ONL Therapeutics Gets Federal Grant of $1 Million
-
After $1M NEI Grant, ONL Therapeutics Closer to Clinical Trials
-
ONL Therapeutics closes $4.25 million in Series A funding
-
ONL Therapeutics Promotes New Lead Drug, Expands Clinical Program
-
ONL Therapeutics Receives Phase II SBIR Grant from National Eye Institute for Development of Novel Retinal Disease Treatment
-
SBIR Award, $1M Investment Get ONL Therapeutics to Clinical Trials
-
Applications for Neuroprotection: The Next Therapeutic Category in Retina Medicine